Medical University of Vienna, Austria.
J Crohns Colitis. 2013 Jul;7(6):429-40. doi: 10.1016/j.crohns.2012.07.031. Epub 2012 Aug 20.
Iron deficiency anemia (IDA) frequently occurs in patients suffering from inflammatory bowel disease (IBD) and negatively impacts their quality of life. Nevertheless, the condition appears to be both under-diagnosed and undertreated. Regular biochemical screening of patients with IBD for anemia by the gastroenterology community has to be advocated. Oral iron is a low cost treatment however its effectiveness is limited by low bioavailability and poor tolerability. Intravenous (IV) iron rapidly replenishes iron stores and has demonstrated its safe use in a number of studies in various therapeutic areas. A broad spectrum of new IV iron formulations is now becoming available offering improved tolerability and patient convenience by rapidly restoring the depleted iron status of patients with IBD. The following article aims to review the magnitude of the problem of IDA in IBD, suggest screening standards and highlight existing and future therapies.
缺铁性贫血（IDA）在炎症性肠病（IBD）患者中经常发生，对其生活质量产生负面影响。然而，这种情况似乎既被漏诊又治疗不足。需要倡导胃肠病学界定期对 IBD 患者进行贫血的生化筛查。口服铁剂是一种低成本的治疗方法，但其有效性受到生物利用度低和耐受性差的限制。静脉内（IV）铁剂可迅速补充铁储存量，并已在多个治疗领域的多项研究中证明其安全使用。现在有广泛的新型 IV 铁制剂可供使用，通过迅速恢复 IBD 患者耗尽的铁状态，提供更好的耐受性和患者便利性。本文旨在综述 IBD 中 IDA 的问题严重程度，提出筛查标准，并强调现有的和未来的治疗方法。
